← Back to Screener
Elicio Therapeutics, Inc. Common Stock (ELTX)
Price$13.26
Growth ScoreF
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)33.74%
Price vs S&P 500 (4W)33.81%
VGM Score41.68
Market Capitalization$253.08M
All Metrics
Book Value / Share (Quarterly)$0.09
P/TBV (Annual)1.15x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.07
Price vs S&P 500 (YTD)58.43%
Gross Margin (TTM)98.48%
Net Profit Margin (TTM)-81.45%
EPS (TTM)$-2.41
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-2.41
EPS (Annual)$-4.33
ROI (Annual)-309.46%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-1577.53%
Cash / Share (Quarterly)$0.80
ROA (Last FY)-184.54%
Revenue Growth TTM (YoY)-91.88%
EBITD / Share (TTM)$-2.25
Operating Margin (TTM)-83.03%
Cash Flow / Share (Annual)$-2.08
P/B Ratio154.70x
P/B Ratio (Quarterly)85.10x
Net Income / Employee (Annual)$-1,575,800
Net Interest Coverage (TTM)-663.06x
ROA (TTM)-151.12%
EPS Incl Extra (Annual)$-4.33
Current Ratio (Annual)2.38x
Quick Ratio (Quarterly)2.07x
3-Month Avg Trading Volume0.14M
52-Week Price Return77.51%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.59
P/S Ratio (Annual)110.04x
Asset Turnover (Annual)0.04x
52-Week High$14.97
Operating Margin (5Y Avg)-1344.62%
EPS Excl Extra (Annual)$-4.33
CapEx CAGR (5Y)-16.74%
26-Week Price Return41.67%
Quick Ratio (Annual)2.29x
13-Week Price Return12.18%
Total Debt / Equity (Annual)5.75x
Current Ratio (Quarterly)2.24x
Enterprise Value$247.61M
Asset Turnover (TTM)0.33x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1687.39%
Cash / Share (Annual)$1.04
3-Month Return Std Dev90.20%
Gross Margin (5Y Avg)80.96%
Net Income / Employee (TTM)$-1,217,700
ROE (Last FY)-309.46%
Net Interest Coverage (Annual)-62.99x
EPS Basic Excl Extra (Annual)$-4.33
Total Debt / Equity (Quarterly)5.75x
EPS Incl Extra (TTM)$-2.41
Receivables Turnover (Annual)5.71x
ROI (TTM)-354.47%
P/S Ratio (TTM)8.52x
Pretax Margin (5Y Avg)-1577.53%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$14.54
Price vs S&P 500 (52W)53.14%
Year-to-Date Return66.58%
5-Day Price Return9.41%
EPS Normalized (Annual)$-4.33
ROA (5Y Avg)-122.69%
Net Profit Margin (Annual)-1687.39%
Month-to-Date Return15.91%
Cash Flow / Share (TTM)$-7.66
EBITD / Share (Annual)$-3.72
Operating Margin (Annual)-1722.61%
LT Debt / Equity (Annual)5.75x
LT Debt / Equity (Quarterly)5.75x
EPS Basic Excl Extra (TTM)$-2.41
P/TBV (Quarterly)3.80x
P/B Ratio (Annual)85.10x
Pretax Margin (TTM)-81.45%
Book Value / Share (Annual)$0.09
Price vs S&P 500 (13W)3.93%
Beta1.12x
Revenue / Share (TTM)$0.00
ROE (TTM)-977.67%
52-Week Low$7.37
gGradeF
mGradeA
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.65est. -0.47
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ELTXElicio Therapeutics, Inc. Common Stock | — | F | A | $13.26 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Elicio Therapeutics is a clinical-stage biotechnology company developing cancer immunotherapies using its proprietary Amphiphile (AMP) platform, which delivers treatments directly to lymph nodes. The company targets biologically validated but traditionally hard-to-drug cancer targets for patients with limited treatment options.